Dazdotuftide TFA | CAS 2522933-45-3 | Immunomodulator for Inflammatory Research

Description

Product Description

Dazdotuftide TFA is a synthetic peptide specifically designed to modulate the immune system at multiple levels. Its activity includes the regulation of cytokine expression, modulation of lymphocyte proliferation, and the orchestration of inflammatory signaling pathways. In vitro studies demonstrate that Dazdotuftide TFA can influence T-cell activation, B-cell responses, and the functional activity of antigen-presenting cells, making it a versatile tool for immunological investigations.

Mechanistically, Dazdotuftide TFA exerts effects by binding to immune cell surface receptors, influencing downstream intracellular signaling cascades, and ultimately regulating gene transcription of key immune mediators. It has been used in models exploring autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease. Additionally, Dazdotuftide TFA is applied in studies on inflammation-driven tissue injury, immune tolerance, and therapeutic immunomodulation.

The peptide is provided as a lyophilized powder with a purity of ≥99%, ensuring consistent experimental results. Its solubility in aqueous and polar solvents such as PBS and DMSO allows compatibility with various laboratory techniques, including cell culture assays, ELISA, flow cytometry, and high-throughput immunoassays. Dazdotuftide TFA’s stability under recommended storage conditions ensures long-term reliability for both short-term studies and extended experimental designs.

By modulating immune cell activity, Dazdotuftide TFA provides researchers with a unique platform to probe mechanistic questions in immunology, evaluate potential therapeutic targets, and develop proof-of-concept studies for novel immunotherapies. Its precise and reproducible effects make it ideal for translational research bridging basic immunology and clinical applications.

Product Specifications

Mechanism of Action

Dazdotuftide TFA operates through multiple immunological mechanisms that collectively contribute to its immunomodulatory activity. It engages receptors on T cells, B cells, dendritic cells, and macrophages to regulate intracellular signaling pathways such as NF-κB, MAPK, and JAK/STAT. By modulating these pathways, Dazdotuftide TFA alters the transcriptional programs controlling cytokine production, chemokine secretion, and immune cell differentiation.

In preclinical studies, Dazdotuftide TFA has been shown to suppress overactive inflammatory responses while enhancing immune surveillance. For example, in T-cell models, it promotes the differentiation of regulatory T cells (Tregs) and inhibits the proliferation of effector T cells in autoimmune-like environments. In macrophage cultures, it can shift polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, reducing the production of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β.

This dual modulatory activity enables researchers to investigate the complex interplay between pro- and anti-inflammatory signals and to model both autoimmune pathologies and chronic inflammation. Furthermore, Dazdotuftide TFA’s ability to affect antigen presentation and immune cell crosstalk provides a platform for exploring novel combination therapies and immunotherapeutic interventions.

Side Effects

Dazdotuftide TFA is strictly for laboratory research and should be handled according to biosafety protocols. Potential cellular responses include altered cytokine expression, shifts in immune cell population dynamics, and modulation of inflammatory pathways. Experimental results may vary depending on cell type, concentration, and treatment duration.

It is important to note that Dazdotuftide TFA has not been evaluated for clinical or therapeutic use. Researchers must avoid direct human or animal administration. Standard laboratory precautions, including personal protective equipment and proper waste disposal, are required when handling this peptide. Any observed cytotoxicity or off-target effects should be interpreted within the context of experimental models.

Due to its potent immunomodulatory activity, Dazdotuftide TFA may also affect co-cultured cell populations or interact with other immunologically active compounds, necessitating careful experimental design and controls.

Keywords

Dazdotuftide TFA, TRS01 TFA, immunomodulator peptide, immune signaling research, inflammation research compound, autoimmune research agent

Shipping Guarantee

All shipments are handled using validated cold-chain logistics to preserve peptide integrity. Each package is sealed in moisture-proof containers with secondary protective wrapping and continuous temperature monitoring. Products are shipped via express international couriers with full tracking and insurance coverage.

Trade Assurance

We ensure product authenticity, verified ≥99% purity, and compliance with analytical standards (HPLC, MS, and NMR). Each batch is supplied with a Certificate of Analysis (CoA). Our trade assurance policy guarantees replacement or refund for any deviation from listed specifications.

Payment Support

We provide flexible and secure global payment options to support international research transactions. Accepted payment methods include PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are protected by industry-standard encryption and verified payment gateways to ensure confidentiality and fund security.

Disclaimer

All products listed are intended for laboratory research use only and not for human or veterinary use. They are not drugs, medical devices, or diagnostics and should not be administered to humans or animals. Researchers must handle all materials in accordance with institutional biosafety and chemical safety guidelines. The information provided is for scientific reference only and does not imply therapeutic efficacy, safety, or regulatory approval.